Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered

P.N.R. Dekhuijzen, M. Decramer

ABSTRACT: Skeletal muscle myopathy is a well-known side-effect of systemically administered corticosteroids. In recent years, renewed attention is being paid to the involvement of the respiratory muscles and its significant consequence in pulmonary patients. Two different clinical patterns of steroid-induced muscular changes are known. In acute myopathy and atrophy after short-term treatment with high doses of steroids, generalized muscle atrophy and rhabdomyolysis occur, including the respiratory muscles. Chronic steroid myopathy, occurring after prolonged treatment with moderate doses, is characterized by the gradual onset of proximal limb muscle weakness and may be accompanied by reduced respiratory muscle force.

Animal studies demonstrated diaphragmatic myopathy and atrophy similar to the alterations in peripheral skeletal muscles. Fluorinated steroids induced selective type IIB (fast-twitch glycolytic) fibre atrophy, resulting in changes in contractile properties of the diaphragm. Non-fluorinated steroids may also induce histological, biochemical and functional alterations in the diaphragm. Observations in patients with collagen vascular disorders and with asthma and chronic obstructive pulmonary disease (COPD) underline the potential hazards of treatment with corticosteroids to respiratory muscle structure and function.

In the present review, literature on corticosteroid-induced pathological and physiological changes in respiratory muscles will be discussed, as well as their potential clinical relevance and implications for therapy.

Clinical picture of steroid-induced myopathy

Two distinct types of steroid-induced myopathy are well-known to the clinician: acute and chronic steroid myopathy.

Acute steroid myopathy

This complication of treatment with systemic corticosteroids is infrequently encountered [16–20]. Generalized muscle weakness, involving the respiratory muscles, occurs 5–7 days after the onset of treatment with high doses of corticosteroids (e.g. hydrocortisone 0.9–4 g·day\(^{-1}\) i.v, dexamethasone 40–80 mg·day\(^{-1}\) i.v.

Intravenous and oral corticosteroids are often used in the treatment of obstructive pulmonary disease, interstitial lung disease, and collagen vascular disorders. Among the many side-effects are myopathy and atrophy, affecting striated muscles of the limbs. This occurs primarily when fluorinated steroids such as triamcinolone and dexamethasone are used [1–3]. In patients, proximal muscle wasting and weakness predominate the clinical picture. Biopsy studies of peripheral muscles in humans and animals show selective atrophy of the type IIB (fast-twitch glycolytic) fibres [3–7]. Due to their continuous activity the respiratory muscles, especially the diaphragm, were thought to be relatively spared by this process.

In recent years, however, several studies in animals have shown that diaphragmatic structure and function may be severely compromised by the use of systemic steroids [8–12]. Diaphragmatic atrophy and weakness were the main findings in these animal studies.

The extent to which diaphragmatic function may be compromised by steroid administration in patients is not fully understood [13–15]. The clinical implications of these changes, however, may be potentially serious in patients with chronic obstructive pulmonary disease (COPD) and asthma. In these patients, diaphragmatic function is already affected by hyperinflation, hypoxaemia, hypercapnia and malnutrition. Moreover, a reduced average activity level of these patients will lead to the development of disuse atrophy.

In the present review, literature on corticosteroid-induced pathological and physiological changes in respiratory muscles will be discussed, as well as their potential clinical relevance and implications for therapy.

Correspondence: M. Decramer, Respiratory Division, University Hospital, Weligerveid 1, 3212 Pellenberg, Belgium

Keywords: Atrophy corticosteroids myopathy respiratory muscles

Received: January 20 1992
Accepted for publication May 7 1992

This study was supported by grants from the Dutch Asthma Foundation and the "Nationale Fonds voor Wetenschappelijk Onderzoek".
In one study [20], there appeared to be a correlation between the occurrence of this complication and the total dose of steroids administered. Acute atrophy was encountered with total doses >5.4 g of hydrocortisone in six days, whereas no signs of myopathy were noted with total doses <4 g [20].

In most cases, high levels of creatine kinase were found (1,000–100,000 U·L⁻¹), associated to myoglobinuria, indicating rhabdomyolysis. Muscle biopsies show focal and diffuse necrosis and atrophy of all fibre types [17, 19], without predilection for type Iib fibres. Previous use of systemic corticosteroids was apparently not involved in the development of this rare complication of steroid therapy. Recovery may be prolonged to more than six months [19].

**Chronic steroid myopathy**

This is the classical type of steroid-induced myopathy, occurring after prolonged administration of prednisolone in a dose of about 40–60 mg·day⁻¹. Proximal muscle weakness is a prominent clinical feature, preventing patients from climbing stairs or elevating their arms. Fluorinated steroids (such as triamcinolone and dexamethasone) seem to produce weakness and myopathy more often than non-fluorinated corticosteroids such as hydrocortisone and prednisone [1–3].

Serum levels of muscle enzymes (creatine kinase (CK), serum glutamic oxalo-acetic transaminase (SGOT) and aldolase) are usually normal [2, 3, 21]. Lactate dehydrogenase (LDH), however, was reported to be elevated in one study of patients with systemic lupus erythematosus [22], and in another paper on patients with COPD or asthma [15]. Creatine excretion in the urine is massively increased, from several days before the clinical appearance of myopathy [3]. Myoglobinuria or rhabdomyolysis are absent. In biopsies of the diseased muscles, the main finding is an atrophy of type Iib fast-twitch glycolytic (FG) fibres [3–7].

The distribution of the different fibre types, however, was not changed [7, 23, 24]. Recovery of weakness associated with chronic use of steroids may take many weeks or months [25].

Corticosteroids preferentially affect less active muscles [26]. Moreover, muscles with predominantly type Iib fibres are especially susceptible to steroid-induced wasting [27, 28]. In this respect the almost continuously active diaphragm, mainly composed of type I and Iia fibres, would not be expected to be affected by corticosteroids. Recent animal studies, however, have cast doubt on this expectation.

**Respiratory muscle involvement in animal studies**

The effects of steroids on physiological, histochemical and biochemical characteristics of the diaphragm have been described in several animal studies. The results of these studies are summarized in tables 1, 2 and 3. Moore et al. [8] investigated the effects of cortisone on the diaphragm in rats (table 1). After daily intramuscular injection of 100 mg·kg⁻¹ cortisone acetate for ten days the weight of the diaphragm decreased by about 30%. The force generating capacity of the diaphragm decreased in proportion to the reduction in weight, but it was not altered when expressed per unit cross-sectional area (table 2). During the force-frequency curve fatigue (i.e. a reduction in maximal fused tetanic tension) occurred in the control groups, but not in the steroid-treated group. This may be explained by a selective atrophy of the type Iib fibres, leaving muscle mainly composed of fatigue-resistant type I and Iia fibres.

The effects of treatment over two weeks with cortisone acetate (10 mg·kg⁻¹ q·d.) on the diaphragm and the m. extensor digitorum longus (EDL), (a limb muscle mainly composed of fast-twitch Ila and IIb fibres) of rabbits were studied by Ferguson et al. [11].

<table>
<thead>
<tr>
<th>Animal</th>
<th>Steroid dose, duration</th>
<th>Body weight</th>
<th>Diaphragm weight</th>
<th>Soleus weight</th>
<th>Gastrocnemius weight</th>
<th>EDL weight</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rats 11</td>
<td>cortisone acetate i.m.</td>
<td></td>
<td>-14%</td>
<td>-30%</td>
<td>-36%</td>
<td>-28%</td>
<td>Moore et al. [8]</td>
</tr>
<tr>
<td></td>
<td>100 mg·kg⁻¹ q·d. 10 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hamsters 4</td>
<td>triamcinolone i.m.</td>
<td></td>
<td>-27%</td>
<td>-</td>
<td>-</td>
<td>-45%</td>
<td>Wilcox et al. [9]</td>
</tr>
<tr>
<td></td>
<td>3 mg·kg⁻¹ q·d. 3 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rats 80</td>
<td>triamcinolone i.m.</td>
<td></td>
<td>-30%</td>
<td>-30%</td>
<td>-</td>
<td>-27%</td>
<td>Vures et al. [10]</td>
</tr>
<tr>
<td></td>
<td>1.2 mg·kg⁻¹ q·d. 8 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rats 10</td>
<td>dexamethasone i.p.</td>
<td></td>
<td>-18%</td>
<td>-30%</td>
<td>-</td>
<td>-</td>
<td>Sasson et al. [12]</td>
</tr>
<tr>
<td></td>
<td>1 mg·kg⁻¹ q·d. 2 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rats 9</td>
<td>dexamethasone i.p.</td>
<td></td>
<td>-23%</td>
<td>-32%</td>
<td>-</td>
<td>-</td>
<td>Sasson et al. [12]</td>
</tr>
<tr>
<td></td>
<td>4 mg·kg⁻¹ q·d. 2 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rats 7</td>
<td>dexamethasone i.p.</td>
<td></td>
<td>-25%</td>
<td>-26%</td>
<td>-28%</td>
<td>-</td>
<td>Sasson et al. [12]</td>
</tr>
<tr>
<td></td>
<td>1 mg·kg⁻¹ q·d. 7 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

EDL: m. extensor digitorum longus; =: no change; -: not measured.
Steroid myopathy and respiratory disease

Table 2. Diaphragmatic contractile properties

<table>
<thead>
<tr>
<th>Animal</th>
<th>Steroid</th>
<th>Dose, duration</th>
<th>Pt/CSA</th>
<th>Po/CSA</th>
<th>Pt/Po</th>
<th>TPT 1/2 RT</th>
<th>Force freq. curve</th>
<th>Fatigue</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rats</td>
<td>cortisone acetate</td>
<td>i.m. 100 mg·kg⁻¹ q.d. 10 days</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
</tr>
<tr>
<td>Hamsters</td>
<td>triamcinolone</td>
<td>i.m. 3 mg·kg⁻¹ q.d. 3 weeks</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>+20%</td>
<td>+31% ↑ at 10, 20, 30 Hz</td>
<td>↓</td>
<td>=</td>
</tr>
<tr>
<td>Rats</td>
<td>triamcinolone</td>
<td>i.m. 1.2 mg·kg⁻¹ q.d. 8 days</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
</tr>
<tr>
<td>Rats</td>
<td>dexamethasone</td>
<td>i.p. 1 mg·kg⁻¹ q.d. 2 weeks</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
</tr>
<tr>
<td>Rats</td>
<td>dexamethasone</td>
<td>i.p. 4 mg·kg⁻¹ q.d. 2 weeks</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
</tr>
<tr>
<td>Rats</td>
<td>dexamethasone</td>
<td>i.p. 1 mg·kg⁻¹ q.d. 7 weeks</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
<td>=</td>
</tr>
</tbody>
</table>

Pt: twitch tension; CSA: cross-sectional area; Po: tetanic tension; TPT: time-to-peak tension; 1/2 RT: half-relaxation time.
=: no change; -: not measured.

Table 3. Histological, histochemical and biochemical changes in the diaphragm

<table>
<thead>
<tr>
<th>Animal</th>
<th>Steroid</th>
<th>Dose, duration</th>
<th>Gross pathology</th>
<th>Histochemistry</th>
<th>Biochemistry</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbits</td>
<td>cortisone acetate</td>
<td>i.m. 10 mg·kg⁻¹ q.d. 2 weeks</td>
<td>Vacuolization</td>
<td>Fragmentation</td>
<td>Myonecrosis</td>
<td>Glycogen ↑</td>
</tr>
<tr>
<td>Rabbits</td>
<td>cortisone acetate</td>
<td>i.m. 10 mg·kg⁻¹ q.d. 3 weeks</td>
<td>Vacuolization</td>
<td>Myonecrosis</td>
<td>Fibre types =</td>
<td>Glycogen ↑</td>
</tr>
<tr>
<td>Hamsters</td>
<td>triamcinolone</td>
<td>i.m. 3 mg·kg⁻¹ q.d. 3 weeks</td>
<td>More angulated muscle fibres</td>
<td>Aggregate areas of SDH staining in type I and II fibres</td>
<td></td>
<td>Wilcox et al. [9]</td>
</tr>
</tbody>
</table>

CSA: cross-sectional area; SDH: succinate dehydrogenase. =: no change; -: not measured.

Weight loss did not occur in these animals. Histological examination of the diaphragm showed extensive vacuolization, fragmentation of contractile material and loss of fibre cross-sectional area (table 3). Glycogen and lactate levels were significantly elevated in the diaphragm, whereas in the EDL only lactate was increased. No significant pathological changes occurred in the EDL. Maximal transdiaphragmatic pressure (Pdimax) was not altered by the treatment. Respiratory muscle endurance, measured by inspiratory threshold loading, was significantly decreased. These results indicate that even with a moderate dose of cortisone acetate histological and biochemical changes occur, resulting in a decrease in diaphragmatic endurance but not in strength.

Atrophy of type IIB fibres of the diaphragm, without changes in type I or IIA fibres, was found in hamsters treated with triamcinolone (3 mg·kg⁻¹ q.d.) during two weeks [9]. Triamcinolone induced profound loss of body weight. Maximal force of the diaphragm per unit cross-sectional area did not change. The force-frequency curve shifted to the left; the fatigability of the diaphragm was diminished. These findings are expected to result from the relative increase of type I and IIA fibres, which are less fatigable than the type IIB fibres. The overall effect is expected to be detrimental because of the loss of muscle mass.

Contrasting findings in rabbits, however, were obtained in a later study from Ferguson et al. [29]. In this study 28 rabbits were treated, during three weeks, with cortisone acetate (10 mg·kg⁻¹ q.d. i.m.). In the diaphragm a reduction in size of all fibre types was shown, including type I fibres. Atrophy of type IIB fibres, but not of type I or IIA, was present in intercostal, sternocleidomastoid and EDL muscles. This type I atrophy in the diaphragm may clearly affect the endurance capacity of this muscle. The discrepancy between these findings and the results of Wilcox et al. [9] may, in part, be related to species differences in fibre composition of the diaphragm and the response...
to corticosteroids. Moreover, these differences may further be explained by the use of a non-fluorinated steroid, cortisone acetate [29], in contrast to triamcinolone [9], a fluorinated steroid. The authors also raise the possibility of a different corticosteroid receptor [30] and/or another type I fibre [31] in the diaphragm compared to peripheral and other respiratory muscles.

In another study [10], 80 rats were treated with a single injection of triamcinolone acetate 12 mg·kg⁻¹, representing a daily dose of 1.2 mg·kg⁻¹. After 8 days, total body weight and mass of the diaphragm and EDL decreased in proportion (about 30%). Transdiaphragmatic pressure during bilateral phrenic nerve stimulation at different frequencies and the force-frequency curve in vitro showed no differences in the low frequency range, but a decrease at higher frequencies (50 and 100 Hz) compared to a control group. Significant, but smaller, changes were also noted in the EDL. Transdiaphragmatic peak twitch tension was not changed, but peak tetanic force was significantly decreased in the steroid-treated group. In this model, it is likely that atrophy (reflected by the decreased weights of the muscles) as well as myopathy (indicated by the generation of less force per unit cross-sectional area) were induced.

Several treatment regimens in rats were compared in the study of SASSON et al. [12]: dexamethasone in low dose (1 mg·kg⁻¹ q.d.) and high dose (4 mg·kg⁻¹ q.d.) during two weeks, and prolonged treatment during seven weeks with low dose dexamethasone (1 mg·kg⁻¹ q.d.). Dose-related weight loss was found in all animals. Diaphragm weight loss was noted in the high dose and the prolonged low dose groups. In these two treatment groups, maximal tetanic tension decreased significantly, and the force-frequency relationship was shifted to the right. The recovery from fatigue was not influenced by dexamethasone.

From these animal studies, it is apparent that high doses of fluorinated [9, 10, 12] and non-fluorinated [8, 11] steroids, administered during short periods, may severely affect diaphragmatic structure and function. From the study of FERGUSON et al. [11], it can be concluded that changes may even occur with relatively low doses of cortisone acetate. The effects of long-term treatment with low doses of steroids remain to be investigated, nor has the effect of intermittent therapy consisting of repeated bursts of steroid administration been studied. The latter two questions may be of paramount importance to the treatment of COPD and asthma patients.

Steroid-induced changes in human respiratory muscles

In an early report from BOWYER et al. [32], respiratory and peripheral muscle strength were studied in steroid-dependent asthmatic patients. Maximal inspiratory mouth pressure (Pimax) correlated with hip flexor strength. The authors also reported a good correlation between Pimax and the daily dose of steroids, but did not provide further details on this statement.

PICADO et al. [33] studied the effects of the use of steroids on the strength of the respiratory muscles and the m. deltoideus in patients with asthma. Steroid-dependent patients (n=34), who took an average dose of 12 mg·day⁻¹ during the last 8 yrs were compared to a group of non-steroid dependent asthmatic patients with the same age and sex distribution. Pmax, maximal expiratory mouth pressure (Pmax) and the strength of the m. deltoideus were not significantly different between the two groups. However, steroid myopathy may not necessarily develop with these relatively low doses of corticosteroids. Moreover, the effects of repeated bursts of steroids were not appreciated in this study.

JANSSENS and DECRAMER [13] described two patients with collagen vascular disorders who showed a progressive decrease in Pmax and Pdimax during treatment with steroids. Gradual steroid tapering resulted in clinical improvement and marked increase in maximal mouth pressures, whilst creatinuria decreased.

In a study of 21 patients with COPD or asthma, significant correlations were found between respiratory and peripheral muscle strength and average daily dose of steroids in the last six months [14]. Eight of the 21 patients suffered from generalized muscle weakness. The average daily dose of methylprednisolone during the last six months exceeded 4 mg in seven out of the eight patients, in contrast to only three of the 13 patients with normal muscle strength.

WANG et al. [34] compared the effects of 20 mg prednisolone orally for two weeks in eight normal subjects in a placebo-controlled study. They found no significant effects on Pmax, Pdimax, Pdiameter or inspiratory muscle endurance. It is not excluded, however, that the effects of steroids may be more pronounced in the presence of other factors that affect diaphragmatic function, as in COPD patients. In addition, longer duration of treatment and higher doses may be required to produce effects.

In a recent report, two patients with asthma and one with COPD, who developed myopathy of respiratory and peripheral muscles during treatment with methylprednisolone, were described [15] (figs. 1 and 2). Pmax and Pdimax were reduced to mean 38% and 48% predicted, respectively, whilst quadriceps force was reduced to 31% predicted. Tapering of the dose was followed by an increase to 74% and 92% of Pmax and Pdimax, respectively, after three months. Quadriceps force increased to 62% after six months.

These observations underline the potential hazards of treatment with corticosteroids, and the prolonged duration of recovery after discontinuation of steroid treatment.

Pathogenesis and aetiology of steroid-induced atrophy and myopathy

Pathological examination of muscles of patients treated acutely with high doses of systemic steroids
reveals signs of massive necrosis and rhabdomyolysis of all fibre types [19]. There is a high concentration of glycogen granules in the intermyofibrillar spaces [17]. Whether factors other than dose and type of steroids administered play a role in the development of these changes is unclear. Disuse atrophy has been shown to be associated with an increase of cytoplasmic steroid receptors [35]. It has been postulated that these steroid-induced changes may develop earlier in patients during mechanical ventilation, especially when they are paralysed for some days [20].

In chronic steroid myopathy a distinctly different pattern of pathological changes is found. In this type, selective type IIb fibre atrophy is found [25]. Fibre type distribution is not altered. Electron microscopic examination shows mitochondrial aggregation, swelling and vacuolization, together with myofibrillar degeneration. Muscle spindle atrophy is only found in type II fibres [36].

The aetiology of steroid-induced changes is not entirely clear. Glucocorticoids inhibit protein synthesis and may accelerate myofibrillar and soluble protein degradation in skeletal muscle. These effects are more pronounced in type II than in type I fibres. In addition, carbohydrate metabolism is altered in steroid myopathy. Reduced muscle glycogen phosphorylase activity [5] and increased glycogen synthetase activity [37] lead to an increased intramuscular concentration of glycogen. This impaired glycolytic activity may, in part, be compensated by increasing oxidative metabolism [6]. It might be speculated that the differences in response to steroids are, in part, explained by different contents of oxidative enzymes in type I and IIa fibres compared to type IIb fibres.

**Diagnosis of chronic steroid myopathy**

There is no clear correlation between the dosage or duration of treatment and the development of myopathy. Serum levels of muscle enzymes such as CK, SGOT and aldolase, are usually normal. LDH may sometimes be slightly elevated [15, 22]. The creatine excretion in the urine is strongly elevated, starting several days before the clinical appearance of myopathy [3]. Also, the course of the urine creatine levels may be helpful, in combination with the clinical recovery after discontinuation of the treatment with steroids.

Pulmonary function tests are expected to be similar to those observed in patients with respiratory muscle weakness [38, 39]. A slightly restrictive pattern is found, due to reduced muscle force [13]. The diffusion capacity for carbon dioxide may be reduced because of microatelectases [38]. Lung compliance is reduced with low recoil pressure at total lung capacity (TLC) [38]. This is in contrast with the pattern observed in interstitial lung disease in which elastic recoil pressure at TLC is increased [40]. Measurements of Pimax, Pminax and Pdimax disclose reduced values [14, 15]. Peripheral muscle strength (e.g. quadriceps force) is similarly reduced [15].

Biopsy of peripheral muscle shows selective type IIb atrophy. Muscle glycogen content is increased. Electromyographic findings are nonspecific. The motor unit potentials are of low amplitude and short duration [3, 21, 41].

**Therapy of steroid-induced myopathy**

The treatment of steroid myopathy consists mainly of reduction of the steroid dose, combined with conversion to a non-fluorinated steroid [1–3, 35, 42]. Androgens partially antagonize glucocorticoid-induced muscle atrophy [21, 43, 44], in the diaphragm [45]. The role of these anabolic steroids in patients with COPD or asthma who are treated with glucocorticoids has not yet been elucidated.

Physical exercises, such as weight-lifting [46] and treadmill walking [47] partially prevent steroid-induced atrophy and weakness.
References